Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Registration Statement · S-1

BIOVENTRIX, INC.

BVXXNASDAQEQUITYCurrent

Registration Statement

Filed Feb 12, 2026Accepted Feb 12, 2026, 4:06 PM ESTCIK 1283259Accession 0001493152-26-006407
Share

Company context

We are a medical device company focused on developing, manufacturing and commercializing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction (“HFrEF”).

Current securities

Recent company filings

  1. D/A filingSep 9, 2026
  2. D/A filingSep 1, 2026
  3. S-1/A filingMay 29, 2026
  4. S-1/A filingMay 15, 2026
  5. D filingApr 24, 2026

As-filed source

Primary evidence